Skip to main content

Publications

Your resource for current publications and clinical data demonstrating the utility of the GORE® VIABAHN® Endoprosthesis in practice.

TWELVE-MONTH OUTCOMES FROM THE JAPANESE POST-MARKET SURVEILLANCE STUDY OF THE VIABAHN ENDOPROSTHESIS AS TREATMENT FOR SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE IN THE SUPERFICIAL FEMORAL ARTERIES

Iida O, Ohki T, Soga Y, et al. Twelve-month outcomes from the Japanese post-market surveillance study of the Viabahn Endoprosthesis as treatment for symptomatic peripheral arterial disease in the superficial femoral arteries. Journal of Endovascular Therapy 2022;29(6):855-865.  

LONG-TERM RESULTS OF THE JAPANESE MULTICENTER VIABAHN TRIAL OF HEPARIN BONDED ENDOVASCULAR STENT GRAFTS FOR LONG AND COMPLEX LESIONS IN THE SUPERFICIAL FEMORAL ARTERY

Ohki T, Kichikawa K, Yokoi H, et al. Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery. Journal of Vascular Surgery 2021;74(6):1958-1967.e2.

STENT-GRAFTS ARE THE BEST WAY TO TREAT COMPLEX IN-STENT RESTENOSIS LESIONS IN THE SUPERFICIAL FEMORAL ARTERY: 24-MONTH RESULTS FROM A MULTICENTER RANDOMIZED TRIAL

Bosiers M, Deloose K, Callaert J, et al.  Stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial. Journal of Cardiovascular Surgery 2020;61(5):617-625.

Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE randomized trial

Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators. Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial. Journal of Vascular & Interventional Radiology 2018;30(2):203-211.e4.

Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions

Ohki T, Kichikawa K, Yokoi H, et al. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. Journal of Vascular Surgery 2017;66(1):130-142.e1.  

1-year results of a multicenter randomized controlled trial comparing the Heparin-bonded endoluminal bypass to the femoropopliteal bypass

Reijnen MMPJ, van Walraven LA, Fritschy WM, et al.  1-year results of a multicenter randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass.  JACC: Cardiovascular Interventions 2017;10(22):2320-2331.

SUSTAINED BENEFIT AT 2 YEARS FOR COVERED STENTS VERSUS BARE-METAL STENTS IN LONG SFA LESIONS: THE VIASTAR TRIAL

Lammer J, Zeller T, Hausegger KA, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovascular & Interventional Radiology 2015;38(1):25-32.

HEPARIN-BONDED, EXPANDED POLYTETRAFLUOROETHYLENE-LINED STENT GRAFT IN THE TREATMENT OF FEMOROPOPLITEAL ARTERY DISEASE: 1-YEAR RESULTS OF THE VIPER (VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE IN THE TREATMENT OF SUPERFICIAL FEMORAL ARTERY OBSTRUCTIVE DISEASE) TRIAL

Saxon RR, Chervu A, Jones PA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) Trial. Journal of Vascular & Interventional Radiology 2013;24(2):165 173. 

22800599-EN